Impact on response and survival of DNA repair single nucleotide polymorphisms in relapsed or refractory multiple myeloma patients treated with thalidomide-Reference-Cited by-同舟云学术

Impact on response and survival of DNA repair single nucleotide polymorphisms in relapsed or refractory multiple myeloma patients treated with thalidomide

Published:2011-09 Issue:9 Volume:35 Page:1178-1183
ISSN:0145-2126
Container-title:Leukemia Research
language:en
Short-container-title:Leukemia Research

Author:

Cibeira María Teresa,Fernández de Larrea Carlos,Navarro Alfons,Díaz Tania,Fuster Dolors,Tovar Natalia,Rosiñol Laura,Monzó Mariano,Bladé Joan

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology

Reference41 articles.

1. Thalidomide for treatment of multiple myeloma: 10 years later;Palumbo;Blood,2008

2. Advances in therapy of multiple myeloma;Bladé;Curr Opin Oncol,2008

3. Thalidomide in refractory and relapsing multiple myeloma;Bladé;Semin Oncol,2001

4. Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications;Mitsiades;Blood,2002

5. Bone marrow angiogenesis and angiogenic factors in multiple myeloma treated with novel agents;Cibeira;Cytokine,2008

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The expanding role of gene-based prescribing for phase II drug-metabolizing enzymes;American Journal of Pharmacotherapy and Pharmaceutical Sciences;2023-12-22

2. Role of rs873601 Polymorphisms in Prognosis of Lung Cancer Patients Treated with Platinum-Based Chemotherapy;Biomedicines;2023-11-24

3. The Role of DNA Repair in Genomic Instability of Multiple Myeloma;International Journal of Molecular Sciences;2022-05-19

4. Binding and thermodynamic study of thalidomide with calf thymus DNA: Spectroscopic and computational approaches;International Journal of Biological Macromolecules;2022-05

5. Germline polymorphisms in MGMT associated with temozolomide-related myelotoxicity risk in patients with glioblastoma treated on NRG Oncology/RTOG 0825;Neuro-Oncology Advances;2022-01-01